表紙
市場調查報告書

心臟生物標記檢驗市場:全球機會分析及產業預測 各類型,用途,及檢驗地

Cardiac Biomarkers Testing Market by Type, Application and Location of Testing : Global Opportunity Analysis and Industry Forecast, 2019-2026

出版商 Allied Market Research 商品編碼 881852
出版日期 內容資訊 英文 256 Pages
商品交期: 2-3個工作天內
價格
Back to Top
心臟生物標記檢驗市場:全球機會分析及產業預測 各類型,用途,及檢驗地 Cardiac Biomarkers Testing Market by Type, Application and Location of Testing : Global Opportunity Analysis and Industry Forecast, 2019-2026
出版日期: 2019年05月31日內容資訊: 英文 256 Pages
簡介

這份報告提供全球心臟生物標記檢驗市場的相關調查,市場規模及趨勢和預測,類型·用途·檢驗地方·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 報告的說明
  • 相關利益者的主要優點
  • 主要的市場區隔
  • 調查方法
    • 二次研究
    • 一次研究
    • 分析工具和模式

第2章 摘要整理

  • 主要調查結果
  • CXO的觀點

第3章 市場概要

  • 市場定義和範圍
  • 生物標誌物診斷與傳統診斷相比
  • 評估診斷生物標誌物的關鍵優勢和購買標準
    • 早期診斷
    • 組織特異性診斷
    • 臨床試驗削減
    • 連貫的輸出
  • 心臟生物標記檢驗影響市場的主要趨勢
    • 開發用於風險分層的高靈敏度生物標誌物
    • 心臟生物標記技術的進步:基於血清的生物標誌物
    • 對心臟診斷點的需求不斷增加
  • 整體市場概要
  • 形成心臟生物標記檢驗市場的主力
    • 供應商談判力:高左右
    • 買主談判力:低程度
    • 新加入廠商者的威脅:低程度
    • 替代品的威脅:低程度
    • 競爭激烈度:高左右
  • 價值鏈分析
  • 價格分析
    • 價格分析:各地區
  • 市場演進/產業藍圖
  • 政府的法規
  • 償付的問題
  • 專利分析
    • 各地區
    • 各申請者
  • 市場佔有率分析
  • 案例研究
    • 案例研究
  • 市場趨勢
    • 成長要素
    • 阻礙因素
    • 市場機會

第4章 心臟生物標記檢驗市場:各類型

  • 概要
    • 市場規模及預測
  • 肌酸激酶(CK-MB)
    • 主要的市場趨勢及機會
    • 市場規模及預測
    • 市場分析:各國
  • 肌鈣蛋白
    • 主要的市場趨勢及機會
    • 市場規模及預測
    • 市場分析:各國
  • 肌紅蛋白
    • 主要的市場趨勢及機會
    • 市場規模及預測
    • 市場分析:各國
  • 鈉利尿肽(BNP及NT-proBNP)
    • 主要的市場趨勢及機會
    • 市場規模及預測
    • 市場分析:各國
  • 缺血修飾白蛋白
    • 主要的市場趨勢及機會
    • 市場規模及預測
    • 市場分析:各國
  • 其他
    • 主要的市場趨勢及機會
    • 市場規模及預測
    • 市場分析:各國

第5章 心臟生物標記檢驗市場:各用途

  • 概要
    • 市場規模及預測
  • 心肌梗塞
    • 市場規模及預測
    • 市場分析:各國
  • 鬱血性心衰竭
    • 市場規模及預測
    • 市場分析:各國
  • 急性冠狀動脈症候群
    • 市場規模及預測
    • 市場分析:各國
  • 動脈粥狀硬化
    • 市場規模及預測
    • 市場分析:各國
  • 其他的用途
    • 市場規模及預測
    • 市場分析:各國

第6章 全球心臟生物標記檢驗市場:各檢驗地方

  • 概要
    • 市場規模及預測
  • 就地檢驗
    • 市場規模及預測
    • 市場分析:各國
  • 實驗室檢驗
    • 市場規模及預測
    • 市場分析:各國

第7章 心臟生物標記檢驗市場:各地區

  • 概要
    • 市場規模與預測
  • 北美
    • 主要的市場趨勢與機會
    • 各類型
    • 各用途
    • 各檢驗地方
    • 各國
  • 歐洲
    • 主要的市場趨勢與機會
    • 各類型
    • 各用途
    • 各檢驗地方
    • 各國
  • 亞太地區
    • 主要的市場趨勢與機會
    • 亞洲太平各類型
    • 各用途
    • 各檢驗地方
    • 各國
  • 南美·中東·非洲
    • 主要的市場趨勢與機會
    • 各類型
    • 各用途
    • 各檢驗地方
    • 各國

第8章 企業簡介

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • BioMerieux
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • F. HOFFMANN-LA ROCHE LTD.
  • Siemens AG
  • Thermo Fisher Scientific, Inc.
  • PerkinElmer Inc.
  • Tosoh Corporation
目錄
Product Code: LI_195284

Title:
Cardiac Biomarkers Testing Market by Type (Myocardial Muscle Creatine Kinase, Troponins, Myoglobin, Brain Natriuretic Peptide, Ischemia-modified Albumin, and Others), Application (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others) and Location of Testing (Point of care Testing and Laboratory Testing): Global Opportunity Analysis and Industry Forecast, 2019-2026.

The global cardiac biomarker market generated $7,638 million in 2018, and is projected to reach $18,232 million by 2026, growing at a CAGR of 11.4%. Cardiac biomarkers are protein-based traceable substances used as an indicator of biologic state as well as for diagnostic and prognostic purposes associated with heart. The prevention of cardiac diseases by monitoring heart conditions via cardiac biomarker testing is the profound approach for obtaining rapid results for immediate diagnosing and treatment. Cardiac biomarkers are used as risk stratification for various cardiovascular diseases (CVDs), which include myocardial infraction, congestive heart failure, acute coronary syndrome (ACS), and others. The cardiac biomarkers that are widely used as an integrated diagnostic approach for CVDs include CK-MB, troponin I and T, myoglobin, BNPs, IMA, and others. The global cardiac biomarkers testing market has witnessed a greater demand over the past five to six years.

The ability of cardiac markers for accurate and rapid prediction of heart failure after the onset of chest pain acts as a key factor that boosts the growth of the global cardiac market. In addition, promising features such as high accuracy, quick outcomes, and economic pricing of cardiac point of care (POC) testing drive the market growth. To keep the momentum of cardiac marker tests, key manufacturers offer customized solutions, thus propelling the growth of the market. The commercial application of multi-menu options for cardiac testing using different combinations of cardiac biomarkers and target-oriented solutions serves as the key opportunity for market expansion. However, limited specificity in some cases and side effects such as skeletal muscle injury restrain the growth of the cardiac biomarkers testing market.

The global cardiac biomarker market is segmented based on type, application, location of testing, and region. By type, the market is fragmented into myocardial muscle creatine kinase (CK-MB), troponins (T and I), myoglobin, brain natriuretic peptide (BNPs) or NT-proBNP, ischemia modified albumin (IMA), and others. Depending on application, it is categorized into myocardial infarction, congestive heart failure, acute coronary syndrome, atherosclerosis, and others. By location of testing, it is bifurcated into point of care testing and laboratory testing. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • This report highlights the market dynamics to understand the global cardiac biomarker market and capitalize on the prevailing opportunities.
  • Quantitative analysis of the current market and forecasts assists stakeholders to design business strategies accordingly.
  • Porter's five forces analysis examines the competitive market structure and provides a deeper understanding of the influencing factors for entry and expansion.
  • Pin-point analysis of geographical segments offers identification of most profitable segments to capitalize on.

KEY MARKET SEGMENTS

By Type

  • Myocardial Muscle Creatine Kinase (CK-MB)
  • Troponins (T and I)
  • Myoglobin
  • Brain Natriuretic Peptide (BNPs) or NT-proBNP
  • Ischemia-modified Albumin (IMA)
  • Others

By Application

  • Myocardial Infarction
  • Congestive Heart Failure
  • Acute Coronary Syndrome
  • Atherosclerosis
  • Others

By Location of Testing

  • Point of Care Testing
  • Laboratory Testing

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • Spain
    • Italy
    • UK
    • Rest of Europe
  • Asia-Pacific
    • Australia
    • Japan
    • India
    • China
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East
    • Africa

KEY MARKET PLAYERS

  • Roche Diagnostics
  • Abbott Laboratories
  • Siemens Healthcare
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories
  • BioMerieux
  • PerkinElmer Inc.
  • Tosoh Corporation
  • Danaher Corporation
  • Thermo Fisher Scientific

The other players in the value chain include (profiles not included in the report):

  • Randox Laboratories
  • Johnson and Johnson
  • Olympus Corporation
  • BG Medicines
  • ACS Biomarker B.V.
  • Cavadis Biomedical.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key benefits for stakeholders
  • 1.3. Key market segments
  • 1.4. Research methodology
    • 1.4.1. Secondary research
    • 1.4.2. Primary research
    • 1.4.3. Analyst tools & models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. Key findings
    • 2.1.1. Top impacting factors
    • 2.1.2. Top investment pockets
  • 2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Biomarker diagnosis vs. conventional diagnosis
  • 3.3. Assessment of key advantages and buying criteria for diagnostic biomarkers
    • 3.3.1. Early diagnosis
    • 3.3.2. Tissue specific diagnosis
    • 3.3.3. Reduce clinical trials
    • 3.3.4. Consistent output
  • 3.4. Key trends impacting the Cardiac biomarker testing market
    • 3.4.1. Development of high sensitive biomarkers for risk stratification
    • 3.4.2. Technological advancements in the cardiac biomarkers: Serum based biomarkers
    • 3.4.3. Increasing demand for point of care cardiac diagnostics
  • 3.5. Parent Market Overview
  • 3.6. Key Forces Shaping Cardiac biomarker testing market
    • 3.6.1. High bargaining power of suppliers
    • 3.6.2. Low bargaining power of buyers
    • 3.6.3. Low threat of new entrants
    • 3.6.4. Low threat of substitutes
    • 3.6.5. High intensity of rivalry
  • 3.7. Value chain analysis
  • 3.8. Pricing Analysis
    • 3.8.1. Pricing Analysis, By Region, 2018 & 2025
  • 3.9. Market evolution/Industry roadmap
  • 3.10. Government regulations
  • 3.11. Reimbursement issues
  • 3.12. Patent Analysis
    • 3.12.1. By Region (2016-2018)
    • 3.12.2. By Applicant
  • 3.13. Market share analysis
  • 3.14. Case Studies
    • 3.14.1. Case Study
  • 3.15. Market dynamics
    • 3.15.1. Drivers
      • 3.15.1.1. Increasing prevalence of cardiovascular diseases
      • 3.15.1.2. Cost effective
      • 3.15.1.3. Non-invasive
      • 3.15.1.4. Accuracy prediction
      • 3.15.1.5. Technological advancements using cardiac biomarkers combinations
      • 3.15.1.6. Increasing point of care (POC) testing
    • 3.15.2. Restraints
      • 3.15.2.1. Government Regulation
      • 3.15.2.2. Conformation in result
      • 3.15.2.3. Complex process
    • 3.15.3. Opportunities
      • 3.15.3.1. Personalized medicine
      • 3.15.3.2. Point of care (POCT) testing using cardiac biomarkers

CHAPTER 4: CARDIAC BIOMARKER TESTING MARKET, BY TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Creatine kinase (CK-MB)
    • 4.2.1. Key market trends and opportunities
    • 4.2.2. Market size and forecast
    • 4.2.3. Market analysis, by country
  • 4.3. Troponins
    • 4.3.1. Key market trends and opportunities
    • 4.3.2. Market size and forecast
    • 4.3.3. Market analysis, by country
  • 4.4. Myoglobin
    • 4.4.1. Key market trends and opportunities
    • 4.4.2. Market size and forecast
    • 4.4.3. Market analysis, by country
  • 4.5. Natriuretic peptides (BNP and NT-proBNP)
    • 4.5.1. Key market trends and opportunities
    • 4.5.2. Market size and forecast
    • 4.5.3. Market analysis, by country
  • 4.6. Ischemia modified albumin
    • 4.6.1. Key market trends and opportunities
    • 4.6.2. Market size and forecast
    • 4.6.3. Market analysis, by country
  • 4.7. Others
    • 4.7.1. Key market trends and opportunities
    • 4.7.2. Market size and forecast
    • 4.7.3. Market analysis, by country

CHAPTER 5: CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Myocardial infarction
    • 5.2.1. Market size and forecast
    • 5.2.2. Market analysis, by country
  • 5.3. Congestive heart failure
    • 5.3.1. Market size and forecast
    • 5.3.2. Market analysis, by country
  • 5.4. Acute coronary syndrome
    • 5.4.1. Market size and forecast
    • 5.4.2. Market analysis, by country
  • 5.5. Atherosclerosis
    • 5.5.1. Market size and forecast
    • 5.5.2. Market analysis, by country
  • 5.6. Other applications
    • 5.6.1. Market size and forecast
    • 5.6.2. Market analysis, by country

CHAPTER 6: CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Point of care testing
    • 6.2.1. Market size and forecast
    • 6.2.2. Market analysis, by country
  • 6.3. Laboratory testing
    • 6.3.1. Market size and forecast
    • 6.3.2. Market analysis, by country

CHAPTER 7: CARDIAC BIOMARKER TESTING MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. North America
    • 7.2.1. Key market trends and opportunities
    • 7.2.2. North America market size and forecast, by type
    • 7.2.3. North America market size and forecast, by application
    • 7.2.4. North America market size and forecast, by location of testing
    • 7.2.5. North America market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. U.S. market size and forecast, by type
      • 7.2.5.1.2. U.S. market size and forecast, by application
      • 7.2.5.1.3. U.S. market size and forecast, by location of testing
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Canada market size and forecast, by type
      • 7.2.5.2.2. Canada market size and forecast, by application
      • 7.2.5.2.3. Canada market size and forecast, by location of testing
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Mexico market size and forecast, by type
      • 7.2.5.3.2. Mexico market size and forecast, by application
      • 7.2.5.3.3. Mexico market size and forecast, by location of testing
  • 7.3. Europe
    • 7.3.1. Key market trends and opportunities
    • 7.3.2. Europe market size and forecast, by type
    • 7.3.3. Europe market size and forecast, by application
    • 7.3.4. Europe market size and forecast, by location of testing
    • 7.3.5. Europe market size and forecast, by country
      • 7.3.5.1. UK
      • 7.3.5.1.1. UK market size and forecast, by type
      • 7.3.5.1.2. UK market size and forecast, by application
      • 7.3.5.1.3. UK market size and forecast, by location of testing
      • 7.3.5.2. France
      • 7.3.5.2.1. France market size and forecast, by type
      • 7.3.5.2.2. France market size and forecast, by application
      • 7.3.5.2.3. France market size and forecast, by location of testing
      • 7.3.5.3. Germany
      • 7.3.5.3.1. Germany market size and forecast, by type
      • 7.3.5.3.2. Germany market size and forecast, by application
      • 7.3.5.3.3. Germany market size and forecast, by location of testing
      • 7.3.5.4. Rest of Europe
      • 7.3.5.4.1. Rest of Europe market size and forecast, by type
      • 7.3.5.4.2. Rest of Europe market size and forecast, by application
      • 7.3.5.4.3. Rest of Europe market size and forecast, by location of testing
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends and opportunities
    • 7.4.2. Asia-Pacific market size and forecast, by type
    • 7.4.3. Asia-Pacific market size and forecast, by application
    • 7.4.4. Asia-Pacific market size and forecast, by location of testing
    • 7.4.5. Asia-Pacific market size and forecast, by country
      • 7.4.5.1. China
      • 7.4.5.1.1. China market size and forecast, by type
      • 7.4.5.1.2. China market size and forecast, by application
      • 7.4.5.1.3. China market size and forecast, by location of testing
      • 7.4.5.2. India
      • 7.4.5.2.1. India market size and forecast, by type
      • 7.4.5.2.2. India market size and forecast, by application
      • 7.4.5.2.3. India market size and forecast, by location of testing
      • 7.4.5.3. Australia
      • 7.4.5.3.1. Australia market size and forecast, by type
      • 7.4.5.3.2. Australia market size and forecast, by application
      • 7.4.5.3.3. Australia market size and forecast, by location of testing
      • 7.4.5.4. Japan
      • 7.4.5.4.1. Japan market size and forecast, by type
      • 7.4.5.4.2. Japan market size and forecast, by application
      • 7.4.5.4.3. Japan market size and forecast, by location of testing
      • 7.4.5.5. Rest of Asia-Pacific
      • 7.4.5.5.1. Rest of Asia-Pacific market size and forecast, by type
      • 7.4.5.5.2. Rest of Asia-Pacific market size and forecast, by application
      • 7.4.5.5.3. Rest of Asia-Pacific market size and forecast, by location of testing
  • 7.5. LAMEA
    • 7.5.1. Key market trends and opportunities
    • 7.5.2. LAMEA market size and forecast, by type
    • 7.5.3. LAMEA market size and forecast, by application
    • 7.5.4. LAMEA market size and forecast, by location of testing
    • 7.5.5. LAMEA market size and forecast, by country
      • 7.5.5.1. Latin America
      • 7.5.5.1.1. Latin America market size and forecast, by type
      • 7.5.5.1.2. Latin America market size and forecast, by application
      • 7.5.5.1.3. Latin America market size and forecast, by location of testing
      • 7.5.5.2. Middle East
      • 7.5.5.2.1. Middle East market size and forecast, by type
      • 7.5.5.2.2. Middle East market size and forecast, by application
      • 7.5.5.2.3. Middle East market size and forecast, by location of testing
      • 7.5.5.3. Africa
      • 7.5.5.3.1. Africa market size and forecast, by type
      • 7.5.5.3.2. Africa market size and forecast, by application
      • 7.5.5.3.3. Africa market size and forecast, by location of testing

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Company snapshot
    • 8.1.3. Operating business segments
    • 8.1.4. Product portfolio
    • 8.1.5. Business performance
    • 8.1.6. Key strategic moves and developments
  • 8.2. Becton, Dickinson and Company
    • 8.2.1. Company overview
    • 8.2.2. Company snapshot
    • 8.2.3. Operating business segments
    • 8.2.4. Product portfolio
    • 8.2.5. Business performance
  • 8.3. BioMerieux
    • 8.3.1. Company overview
    • 8.3.2. Company snapshot
    • 8.3.3. Operating business segments
    • 8.3.4. Business performance
  • 8.4. Bio-Rad Laboratories, Inc.
    • 8.4.1. Company overview
    • 8.4.2. Company snapshot
    • 8.4.3. Operating business segments
    • 8.4.4. Business performance
  • 8.5. Danaher Corporation
    • 8.5.1. Company overview
    • 8.5.2. Company snapshot
    • 8.5.3. Operating business segments
    • 8.5.4. Business performance
  • 8.6. F. HOFFMANN-LA ROCHE LTD.
    • 8.6.1. Company overview
    • 8.6.2. Company snapshot
    • 8.6.3. Operating business segments
    • 8.6.4. Business performance
  • 8.7. Siemens AG
    • 8.7.1. Company overview
    • 8.7.2. Company snapshot
    • 8.7.3. Operating business segments
    • 8.7.4. Business performance
  • 8.8. Thermo Fisher Scientific, Inc.
    • 8.8.1. Company overview
    • 8.8.2. Company snapshot
    • 8.8.3. Operating business segments
    • 8.8.4. Business performance
  • 8.9. PerkinElmer Inc.
    • 8.9.1. Company overview
    • 8.9.2. Company snapshot
    • 8.9.3. Operating business segments
    • 8.9.4. Business performance
  • 8.10. Tosoh Corporation
    • 8.10.1. Company overview
    • 8.10.2. Company snapshot
    • 8.10.3. Operating business segments
    • 8.10.4. Business performance

LIST OF TABLES

  • TABLE 01. CONVENTIONAL DIAGNOSTICS VERSUS DIAGNOSTIC BIOMARKER TECHNIQUES
  • TABLE 02. CASE STUDY
  • TABLE 03. APPLICATIONS AND BENEFITS OF POINT OF CARE TESTING
  • TABLE 04. CARDIAC BIOMARKERS FOR CVD IN TNT
  • TABLE 05. CHARACTERISTICS OF CARDIAC BIOMARKER
  • TABLE 06. GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026 ($MILLION)
  • TABLE 07. CARDIAC BIOMARKER TESTING MARKET FOR CREATINE KINASE, BY REGION, 2018-2026 ($MILLION)
  • TABLE 08. CARDIAC BIOMARKER TESTING MARKET FOR ARTHROSPIRA MAXIMA, BY REGION, 2018-2026 ($MILLION)
  • TABLE 09. CARDIAC BIOMARKER TESTING MARKET FOR MYOGLOBIN, BY REGION, 2018-2026 ($MILLION)
  • TABLE 10. CARDIAC BIOMARKER TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP), BY REGION, 2018-2026 ($MILLION)
  • TABLE 11. CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN, BY REGION, 2018-2026 ($MILLION)
  • TABLE 12. CARDIAC BIOMARKER TESTING MARKET FOR OTHERS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 13. GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 14. CARDIAC BIOMARKERS USED FOR MONITORING PATIENTS WITH MYOCARDIAL INFRACTIONS
  • TABLE 15. CARDIAC BIOMARKER TESTING MARKET FOR MYOCARDIAL INFARCTION, BY REGION, 2018-2026, ($MILLION)
  • TABLE 16. CARDIAC BIOMARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY REGION, 2018-2026, ($MILLION)
  • TABLE 17. CARDIAC BIOMARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY REGION, 2018-2026, ($MILLION)
  • TABLE 18. CARDIAC BIOMARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY REGION, 2018-2026, ($MILLION)
  • TABLE 19. CARDIAC BIOMARKER TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2018-2026, ($MILLION)
  • TABLE 20. GLOBAL CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 21. CARDIAC BIOMARKER TESTING MARKET FOR POINT OF CARE TESTING, BY REGION, 2018-2026, ($MILLION)
  • TABLE 22. CARDIAC BIOMARKER TESTING MARKET FOR LABORATORY TESTING, BY REGION, 2018-2026, ($MILLION)
  • TABLE 23. CARDIAC BIOMARKER TESTING MARKET, BY REGION, 2018-2026, ($MILLION)
  • TABLE 24. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 25. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 26. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 27. NORTH AMERICA CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 28. U.S. CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 29. U.S. CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 30. U.S. CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 31. CANADA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 32. CANADA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 33. CANADA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 34. MEXICO CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 35. MEXICO CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 36. MEXICO CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 37. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 38. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 39. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 40. EUROPE CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 41. UK CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 42. UK CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 43. UK CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 44. FRANCE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 45. FRANCE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 46. FRANCE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 47. GERMANY CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 48. GERMANY CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 49. GERMANY CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 50. REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 51. REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 52. REST OF EUROPE CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 53. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 54. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 55. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 56. ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 57. CHINA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 58. CHINA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 59. CHINA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 60. INDIA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 61. INDIA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 62. INDIA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 63. AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 64. AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 65. AUSTRALIA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 66. JAPAN CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 67. JAPAN CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 68. JAPAN CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 71. REST OF ASIA-PACIFIC CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 72. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 73. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 74. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 75. LAMEA CARDIAC BIOMARKER TESTING MARKET, BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 76. LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 77. LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 78. LATIN AMERICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 79. MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 80. MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 81. MIDDLE EAST CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 82. AFRICA CARDIAC BIOMARKER TESTING MARKET, BY TYPE, 2018-2026, ($MILLION)
  • TABLE 83. AFRICA CARDIAC BIOMARKER TESTING MARKET, BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 84. AFRICA CARDIAC BIOMARKER TESTING MARKET, BY LOCATION OF TESTING, 2018-2026, ($MILLION)
  • TABLE 85. ABBOTT: COMPANY SNAPSHOT
  • TABLE 86. ABBOTT: OPERATING SEGMENTS
  • TABLE 87. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 88. BD: COMPANY SNAPSHOT
  • TABLE 89. BD: OPERATING SEGMENTS
  • TABLE 90. BD: PRODUCT PORTFOLIO
  • TABLE 91. BIOMERIEUX, INC.: COMPANY SNAPSHOT
  • TABLE 92. BIOMERIEUX, INC.: OPERATING SEGMENTS
  • TABLE 93. BIO-RAD: COMPANY SNAPSHOT
  • TABLE 94. BIO-RAD: OPERATING SEGMENTS
  • TABLE 95. DANAHER: COMPANY SNAPSHOT
  • TABLE 96. DANAHER: OPERATING SEGMENTS
  • TABLE 97. ROCHE: COMPANY SNAPSHOT
  • TABLE 98. ROCHE: OPERATING SEGMENTS
  • TABLE 99. SEIMENS: COMPANY SNAPSHOT
  • TABLE 100. SEIMENS: PRODUCT SEGMENTS
  • TABLE 101. THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT
  • TABLE 102. THERMO FISHER SCIENTIFIC: OPERATING SEGMENTS
  • TABLE 103. PERKINELMER: COMPANY SNAPSHOT
  • TABLE 104. PERKINELMER: OPERATING SEGMENTS
  • TABLE 105. TOSOH: COMPANY SNAPSHOT
  • TABLE 106. TOSOH: OPERATING SEGMENTS

LIST OF FIGURES

  • FIGURE 01. TOP IMPACTING FACTORS, 2018-2026
  • FIGURE 02. TOP INVESTMENT POCKETS, 2018
  • FIGURE 03. PARENT MARKET
  • FIGURE 04. VALUE CHAIN ANALYSIS OF GLOBAL CARDIAC BIOMARKERS
  • FIGURE 05. PRICING ANALYSIS, BY REGION, 2018 & 2025
  • FIGURE 06. PATENT ANALYSIS, BY REGION
  • FIGURE 07. PATENT ANALYSIS, BY APPLICANT
  • FIGURE 08. MARKET SHARE ANALYSIS, 2018
  • FIGURE 09. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR CREATINE KINASE, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ARTHROSPIRA MAXIMA, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR MYOGLOBIN, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR NATRIURETIC PEPTIDES (BNP AND NT-PROBNP), BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ISCHEMIA MODIFIED ALBUMIN, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR NUTRACEUTICALS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR CONGESTIVE HEART FAILURE, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ACUTE CORONARY SYNDROME, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR ATHEROSCLEROSIS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR POINT OF CARE TESTING, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF CARDIAC BIOMARKER TESTING MARKET FOR LABORATORY TESTING, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 22. ABBOTT: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 23. ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 24. ABBOTT: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 25. BD: NET SALES, 2015-2017 ($MILLION)
  • FIGURE 26. BD: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 27. BD: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
  • FIGURE 28. BIOMERIEUX, INC.: REVENUE, 2015-2017 ($MILLION)
  • FIGURE 29. BIOMERIEUX, INC.: REVENUE SHARE BY APPLICATION, 2017 (%)
  • FIGURE 30. BIOMERIEUX, INC.: REVENUE SHARE BY GEOGRAPHY, 2017 (%)
  • FIGURE 31. BIO-RAD: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 32. BIO-RAD: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 33. BIO-RAD: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
  • FIGURE 34. DANAHER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 35. DANAHER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 36. DANAHER: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 37. ROCHE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 38. ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 39. ROCHE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 40. SEIMENS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 41. SEIMENS: REVENUE SHARE BY PRODUCT SEGMENT, 2018 (%)
  • FIGURE 42. SEIMENS: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
  • FIGURE 43. THERMO FISHER SCIENTIFIC: REVENUE, 2016-2018 ($MILLION)
  • FIGURE 44. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 45. THERMO FISHER SCIENTIFIC: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
  • FIGURE 46. PERKINELMER: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 47. PERKINELMER: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 48. PERKINELMER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
  • FIGURE 49. TOSOH: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 50. TOSOH: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 51. TOSOH: REVENUE SHARE BY REGION, 2018 (%)
Back to Top